Claris Ventures and Exor Ventures Team Up for the Development of Innovative Drugs in Italy
Turin, May 14, 2024 – Claris Ventures and Exor Ventures are joining forces in a new initiative aimed at developing innovative drugs in collaboration with Italian universities and research centers.
The partnership will fund drug discovery and preclinical validation activities while also supporting the subsequent stages towards clinical development. “Our primary goal is to accelerate the development of new pharmacological solutions in therapeutic areas with the highest clinical need, by working alongside researchers from the early stages and leveraging scientific and operational synergies ” says Pietro Puglisi of Claris Ventures.
Claris Ventures, the first Italian VC operator focused on biotech, and Exor Ventures, the VC investment arm of Exor, will be looking for potential drugs and preclinical candidates to add to their development pipeline in the coming months. To this end, researchers from across Italy are invited to submit their ideas and projects through the dedicated online portal www.leverbio.com.
Particular attention will be paid to the expertise of the proposing groups and the availability of preclinical models that enable rapid pharmacological optimization to maximize the synergy between academic research and development activities.
Initially, the initiative will focus on development programs originating from the Italian ecosystem, without excluding the possibility of collaborating with some of the universities and research centers abroad that Claris Ventures and Exor Ventures have previously worked with to launch new biotech companies.
“We are confident that through our partnership with Claris Ventures and the level of ambition inherent in Exor’s DNA, we will have a profound impact on pharmaceutical research and the development of new treatments,” says Noam Ohana of Exor Ventures. “This collaboration represents an important step in our commitment to supporting innovation in the biotech sector, especially in Italy,” adds Ileana Pirozzi of Exor Ventures.